Psoriatic arthritis and psoriasis: Role of patient advocacy organisations in the twenty first century

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Zimmerman, G M ^a   Savage, L M ^b   Chandler, D C ^c   Maccarone Buonfigli, M ^d  

^a National Psoriasis Foundation   (United States)

^b Spondylitis Association of America   (United States)

^c Psoriatic Arthropathy Alliance   (United Kingdom)

^d Assoc Care of People with Psoriasis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CALCIPOTRIOL; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; IMMUNOLOGIC AGENT; INFLIXIMAB; METHOTREXATE; STEROID; TAZAROTENE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; CONFERENCE PAPER; DECISION MAKING; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; MEDICAL RESEARCH; PATIENT EDUCATION; PATIENT SATISFACTION; POLITICS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SUPPORT GROUP;

ARTHRITIS, PSORIATIC; HUMANS; INTERNATIONAL COOPERATION; ORGANIZATIONS, NONPROFIT; PATIENT ADVOCACY; PATIENT EDUCATION; PSORIASIS;

EID: 14244250708     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.033225     Document Type: Conference Paper

References (30)

1. National Psoriasis Foundation. Benchmark Survey, 2001. Portland, OR: National Psoriasis Foundation.
2. National Psoriasis Foundation. Internal Statistical Report, 2004. Portland, OR: National Psoriasis Foundation.
3. National Psoriasis Foundation. Survey Panels, 2004. Portland, OR: National Psoriasis Foundation.
4. National Psoriasis Foundation. Survey Panels, 2003. Portland, OR: National Psoriasis Foundation.
5. Spondylitis Association of America (SAA). Straight Talk an Spondylitis. Sherman Oaks, CA: SAA, 1992.
6. Feldkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000;12:239-47.
7. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Scientific Workshops, Conferences, and Committees Reports. Conference Summary. Ankylosing Spondylitis Research: HLA-B27 and Beyond. Available at www.niams.nin.gov/ne/reports/sci_wrk/1998/b27summ.htm (accessed 31 August 2004).
8. Bruckel J. Spondylitis Association of America. Presented at investigators meeting on AS, New York, 28 August 2002.
9. Diagnosis and management of ankylosing spondylitis, guidelines in rheumatology. A CME enduring material developed to review recent guidelines regarding the assessment and treatment of ankylosing spondylitis. Release date: March 2004; Termination date: March 2005. Supported by an unrestricted grant from Amgen, Inc and Wyeth.
10. Spondylitis Association of America. Spondylitis Plus 2004;5:2.
11. Spondylitis Association of America. Spondylitis Plus 1999;Fall:9.
12. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Highlights. NIAM Shorttakes. Available at www.niams.nih.gov/ne/highlights/ shorttakes/shrtke_2_00.htm (accessed 31 August 2004).
13. Spondylitis Association of America, Annual Membership Survey, 2001-2002.
14. Gladman DD, Brubacher B, Buskila D, Farewell VT. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Genetic and gender effects. Clin Invest Med 1993;16:1-7.
15. Gladman DD, Antani C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(suppl II):ii18-23.
16. Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pnarmacother 2004;5:1881-6.
17. Emery P. Review of health economics modelling in rheumatoid arthritis. Pharmacoeconomics 2004;22(suppl):55-69.
18. Ritchlin CT, Daikh BE. Recent advances in the treatment of the seronegative spondyloarthropathies. Curr Rheumatol Rep 2001;3:399-403.
19. Spondylitis Association of America. AS Life Impact Study 2002.
20. Forrell C. Patient and Public Involvement in Health-The Evidence for Policy Implementation. London, Department of Health, 2004 (available at www.dh.gov.uk).
21. Department of Health. The NHS Plan implementation programme 2001-2. London: Department of Health, 2000. Crown copyright.
22. Psoriatic Arthritis Alliance. Internal Statistical Report, 2003. St Albans, Herts: Psoriatic Arthritis Alliance.
23. TOPSO Study. Skin 'n' Bones Connection 2004;4.
24. Department of Health. The NHS Improvement Plan: Putting people at the heart of public services. London: Department of Health, 2004. Crown copyright.
25. Italian Law N. 226, November 1999.
26. Duffy CM, Watonabe Duffy KN, Gladman DD, Brubacher BB, Buskila D, Langevitz P, et al. The utility of the arthritis impact measurement scales for patients with psoriatic arthritis. J Rheumatol 1992;19:1727-32.
27. Husted JA, Gladman DD, Long JA, Farewell VT. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-43.
28. Giardina E, Novelli G, Costanzo A, Nistico S, Bulli C, Sinibaldi C, et al. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J Invest Dermatol 2004;122:1106-7.
29. Capon F, Semprini S, Chimenti S, Fabrizi G, Zambruno G, Murgia S, et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 2001;116:728-30.
30. Feldtkeller E, Lemmel EM, Russell AS. Ankylosing spondylitis in the pharaohs of ancient Egypt. Rheumatol Int 2003;23:1-5.z.